Dr. Michael R. Cox, MD

Medicare patients and services

Medicare patients, 2024

1,753

Services billed

6,087

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 18 payments worth $3,123 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Kansas →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $498,173 in research payments for these studies, mostly to the institutions running them.

• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  Eli Lilly and Company · Active, not recruiting · NCT05869903
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
  Eli Lilly and Company · Active, not recruiting · NCT06292013
• Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
  Eli Lilly and Company · Completed · NCT06354660
• Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
  Novartis Pharmaceuticals Corporation
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
  Eli Lilly and Company · Completed · NCT04255433
• A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients…
  Alnylam Pharmaceuticals Inc.
• A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
  Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Internal Medicine clinicians in Topeka

• Jamal Akhtar, M.D.
• Ahmad M. Al-tamimi, MBBS
• Joyce M. Allen, M.D.
• Ekta Aneja, MD
• James A. Barnett, MD
• Shravana Bheemanathi, MD
• Julie M. Colvin, MD
• Jeffrey K. Conrow, MD